<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02575248</url>
  </required_header>
  <id_info>
    <org_study_id>fwa000017585</org_study_id>
    <nct_id>NCT02575248</nct_id>
  </id_info>
  <brief_title>Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 2 With and Without Suppression by Dienogest</brief_title>
  <official_title>Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 11 With and Without Suppression by Dienogest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at investigating the fertility outcome of endometriosis suppression with&#xD;
      dienogest 2mg / day for 3 month followed by induction of ovulation for 3 month in&#xD;
      endometriosis patients stage I and II.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study population: Sample size:&#xD;
&#xD;
      Group sample sizes of this study is 155 in group one and 155 in group two achieve 80% power&#xD;
      to detect a difference between the group proportions of 0.10. The proportion in group one&#xD;
      (the treatment group) is assumed to be 0.1000 under the null hypothesis and 0.2000 under the&#xD;
      alternative hypothesis. The proportion in group two (the control group) is 0.1000. The test&#xD;
      statistic used is .the one-sided Z test with un pooled variance. The significance level of&#xD;
      the test was targeted at 0.05&#xD;
&#xD;
      Primary outcome:&#xD;
&#xD;
      Clinical pregnancy rate in endometriosis patients stage I and II undergoing endometriosis&#xD;
      suppression with dienogest 2mg / day for 3 month followed by induction of ovulation for 3&#xD;
      month.&#xD;
&#xD;
      Secondary outcome:&#xD;
&#xD;
      Ovulation rate in endometriosis patients stage I and II undergoing endometriosis suppression&#xD;
      with dienogest 2mg / day for 3 month followed by induction of ovulation for 3 month.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
      All women recruited in this study will have the have a definitive diagnosis of endometriosis&#xD;
      grade I or grade II via laparoscopy just before randomization.&#xD;
&#xD;
      Method of Randomization:&#xD;
&#xD;
      A Computerized generated list from the internet&#xD;
      https://www.sealedenvelope.com/sirnple-randomiser/vl/lists&#xD;
&#xD;
      Allocation concealment:&#xD;
&#xD;
      Closed envelope method by a nurse not participating in the study Intervention It is a&#xD;
      prospective randomized controlled trial. Investigation done after recruitment and before&#xD;
      randomization.&#xD;
&#xD;
      The patients will be randomized in to two groups:&#xD;
&#xD;
      Group A: patients receive dienogest 2 mg (visanne 2mg sanofi Aventis) daily for three months&#xD;
      then followed by induction of ovulation with clomiphene citrate (clomid 5mg sanofi aventis&#xD;
      for three months.&#xD;
&#xD;
      Group B: Patients will undergo induction of ovulation with clomiphene citrate (clomid 50mg&#xD;
      sanofi aventis) for three months.&#xD;
&#xD;
      Protocol of induction of ovulation&#xD;
&#xD;
        1. Clomiphen citrate (clomid 50mg sanofi aventis) will be given on day two of the menstrual&#xD;
           cycle at a dose of 50 mg twice daily for five days.&#xD;
&#xD;
        2. Folliculometry will be performed every other day starting from seventh day of the cycle&#xD;
           till ovulation occurs using a 6 Mhz transvaginal probe till the follicles reach 18 - 20&#xD;
           mm.&#xD;
&#xD;
        3. A trigger of ovulation HCG 10000iu is given IM when the follicles reach 18- 22 mm. The&#xD;
           couple will be advised to have intercourse after 36 hrs then daily for 7 days.&#xD;
&#xD;
        4. Prontogest 400 mg (progest 400 mg Sanofi Aventis) daily vaginal suppository as a luteal&#xD;
           phase support.&#xD;
&#xD;
        5. Pregnancy will be diagnosed quantitative B HCG blood test after 2 days missed period.&#xD;
&#xD;
        6. Clinical pregnancy rate will be diagnosed by TVUS confirmed fetal echo with pulsation at&#xD;
           5-7 weeks gestation.&#xD;
&#xD;
      The sonographer confirming clinical pregnancy will be blinded to both groups. Statistical&#xD;
      Analysis&#xD;
&#xD;
      Statistical Method:&#xD;
&#xD;
      Statistical analysis will be performed using Microsoft Excel version 2010 and statistical&#xD;
      package for social sciences ( SPSS ) for windows version l S.O.&#xD;
&#xD;
      Continious data are to be presented as range, mean and standard deviation (if parametric); or&#xD;
      range; median and inter quartile range (if non - parametric).&#xD;
&#xD;
      Dichotomous or categorical data are to be presented as number and percentage. Difference&#xD;
      between independent is to be estimated using independent student's t-test (for parametric&#xD;
      continuous variables), Manny whitney test U-test (for non -parametric continuous variables)&#xD;
      and Chi-square and test (for categorical variables). Receiver operator characteristics curve&#xD;
      is to be constructed to assess the predictability is to be expressed in terms of sensitivity&#xD;
      , specificity , positive and negative predictive values. Significance level is at 0.05.&#xD;
&#xD;
      Ethical and legal aspects&#xD;
&#xD;
      Delegation of investigator responsibilities:&#xD;
&#xD;
      The investigator will ensure that all persons assisting with the trial are adequately&#xD;
      informed about the protocol, any amendments to the protocol, the study treatments, and their&#xD;
      trial-related duties and functions.&#xD;
&#xD;
      Patient information and informed consent:&#xD;
&#xD;
      Before being admitted to the clinical study, the patient must consent to participate after&#xD;
      the nature, scope and possible consequences of the clinical study have been explained in a&#xD;
      form understandable to her and a written consent will be obtained.&#xD;
&#xD;
      Confidentiality:&#xD;
&#xD;
      Only the patient initials will be recorded in the files, and if the patients name appears on&#xD;
      any other document, it must be kept in a privacy by the investigators. The investigator will&#xD;
      maintain a personal patient identification list (patient initials with the corresponding&#xD;
      patient names) to enable records to be identified.&#xD;
&#xD;
      Protocol approval:&#xD;
&#xD;
      Before the beginning of the study and in accordance with the local regulation followed, the&#xD;
      protocol and all the corresponding documents will be declared for Ethical and Research&#xD;
      approval by the council of the obstetrics Department, Ain Shams University.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>2 months</time_frame>
    <description>fetal life detected by ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovulation rate</measure>
    <time_frame>up to 21 days</time_frame>
    <description>ovulation rate is recorded before triggering</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dienogest 2mg</intervention_name>
    <description>Dienogest 2mg is given daily for 3 months then followed by Clomiphene citrate 5 mg induction of ovulation for three months</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene citrate 5 mg</intervention_name>
    <description>Clomiphene citrate 5 mg for induction of ovulation for three months</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. All women recruited in this study will have the have- a definitive diagnosis of&#xD;
        endometriosis grade I or grade II via laparoscopy just before randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Male factor.&#xD;
&#xD;
          2. Other factors e.g. mullerian duct anomalies, hydrosalpinx.&#xD;
&#xD;
          3. Age &gt; 35 years.&#xD;
&#xD;
          4. Day 3 FSH &gt; 14 mlu/ml or antimullerian hormone &lt;1 ng/1.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>laila fareed, lecturer</last_name>
    <role>Study Director</role>
    <affiliation>01222148471</affiliation>
  </overall_official>
  <overall_official>
    <last_name>mostafa fouad, professor</last_name>
    <role>Study Director</role>
    <affiliation>01226188993</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>sherif Abdelhamid, professor</last_name>
    <phone>01001424742</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noha rabei, professor</last_name>
    <phone>01227174996</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AinShamsU</name>
      <address>
        <city>Abbasia</city>
        <state>C</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>alhassan mo khedr, Assistant lecture</last_name>
      <phone>01006193797</phone>
      <email>hasankhedr@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>September 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Alhassan Mohammad Khedr</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>dienogest</keyword>
  <keyword>infertility</keyword>
  <keyword>endometriosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dienogest</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

